DNA distress creates lethal opportunity in MPN
- PMID: 29284611
- DOI: 10.1182/blood-2017-11-813006
DNA distress creates lethal opportunity in MPN
Conflict of interest statement
Conflict-of-interest disclosure: J.W.T. receives research support from Agios Pharmaceuticals, Array Biopharma, Aptose Biosciences, AstraZeneca, Constellation Pharmaceuticals, Genentech, Gilead, Incyte Corporation, Janssen Pharmaceuticals, Seattle Genetics, Syros, and Takeda Pharmaceutical Company and is a consultant for Leap Oncology.
Comment on
-
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.Blood. 2017 Dec 28;130(26):2848-2859. doi: 10.1182/blood-2017-05-784942. Epub 2017 Oct 17. Blood. 2017. PMID: 29042365 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources

